Autologous peripheral blood stem cell transplantation (PSCT) versus a second intensive consolidation course after a common induction and consolidation course in patients with bad prognosis myelodysplastic syndromes (MDS) and acute myelogenous leukemia secondary (sAML) to MDS of more acute than 6 months duration
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Cytarabine; Etoposide; Idarubicin
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 27 May 2010 Biomarkers information updated
- 26 May 2010 Additional lead trial investigator (De Witte T) identified as reported by ClinicalTrials.gov.
- 10 Oct 2005 New trial record.